{"id":42383,"date":"2025-09-28T10:55:00","date_gmt":"2025-09-28T02:55:00","guid":{"rendered":"https:\/\/flcube.com\/?p=42383"},"modified":"2025-09-28T10:55:01","modified_gmt":"2025-09-28T02:55:01","slug":"leo-pharma-secures-first-greater-bay-area-prescription-for-anzupgo-a-novel-topical-jak-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42383","title":{"rendered":"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor"},"content":{"rendered":"\n<p>Denmark-based dermatology specialist <strong>LEO Pharma A\/S<\/strong> announced that the <strong>Greater Bay Area<\/strong>\u2019s first prescription of its first\u2011in\u2011class topical pan\u2011JAK inhibitor, <strong>Anzupgo (Delgocitinib cream)<\/strong>, was written at the <strong>Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital<\/strong>. The approval, granted under the <strong>Greater Bay Area Access Policy for Drugs and Medical Devices<\/strong> in July\u202f2025, marks the drug\u2019s official entry into mainland Greater Bay Area medical institutions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-is-anzupgo\">What Is Anzupgo?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Therapy<\/strong>: Anzupgo is the first topical medication specifically designed for adults with <strong>moderate\u2011to\u2011severe chronic hand eczema (CHE)<\/strong> who have not responded adequately to, or are unsuitable for, corticosteroid therapy.<\/li>\n\n\n\n<li><strong>Mechanism of Action<\/strong>: The cream inhibits all members of the <strong>Janus kinase (JAK) family<\/strong>\u2014JAK1, JAK2, JAK3, and TYK2\u2014thereby blocking the JAK\u2011STAT signaling cascade that drives CHE pathogenesis.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-and-market-context\">Regulatory and Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Greater Bay Area Access<\/strong>: The drug\u2019s approval follows the region\u2019s expedited access policy, which aims to accelerate the availability of innovative therapies across Guangdong, Hong\u202fKong, and Macao.<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong>: By offering a steroid\u2011free option, Anzupgo addresses a significant unmet need among patients who experience steroid\u2011related adverse events or have contraindications to systemic or topical steroids.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications-for-leo-pharma\">Strategic Implications for Leo\u202fPharma<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regional Lead<\/strong>: Securing the first prescription in the Greater Bay Area positions Leo\u202fPharma as a front\u2011runner in dermatological innovation within the high\u2011growth Chinese market.<\/li>\n\n\n\n<li><strong>Pipeline Momentum<\/strong>: The success of Anzupgo may accelerate the company\u2019s broader portfolio of JAK\u2011targeted therapies and strengthen its competitive stance against other biologics and small\u2011molecule agents in dermatology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Denmark-based dermatology specialist LEO Pharma A\/S announced that the Greater Bay Area\u2019s first prescription of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42384,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[65,91,819],"class_list":["post-42383","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug","tag-auto-immune","tag-boao-lecheng-pilot-zone","tag-leo-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based dermatology specialist LEO Pharma A\/S announced that the Greater Bay Area\u2019s first prescription of its first\u2011in\u2011class topical pan\u2011JAK inhibitor, Anzupgo (Delgocitinib cream), was written at the Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital. The approval, granted under the Greater Bay Area Access Policy for Drugs and Medical Devices in July\u202f2025, marks the drug\u2019s official entry into mainland Greater Bay Area medical institutions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42383\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor\" \/>\n<meta property=\"og:description\" content=\"Denmark-based dermatology specialist LEO Pharma A\/S announced that the Greater Bay Area\u2019s first prescription of its first\u2011in\u2011class topical pan\u2011JAK inhibitor, Anzupgo (Delgocitinib cream), was written at the Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital. The approval, granted under the Greater Bay Area Access Policy for Drugs and Medical Devices in July\u202f2025, marks the drug\u2019s official entry into mainland Greater Bay Area medical institutions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42383\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-28T02:55:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-28T02:55:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor\",\"datePublished\":\"2025-09-28T02:55:00+00:00\",\"dateModified\":\"2025-09-28T02:55:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383\"},\"wordCount\":282,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2802.webp\",\"keywords\":[\"Auto-immune\",\"Boao Lecheng pilot zone\",\"LEO Pharma\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42383#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42383\",\"name\":\"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2802.webp\",\"datePublished\":\"2025-09-28T02:55:00+00:00\",\"dateModified\":\"2025-09-28T02:55:01+00:00\",\"description\":\"Denmark-based dermatology specialist LEO Pharma A\\\/S announced that the Greater Bay Area\u2019s first prescription of its first\u2011in\u2011class topical pan\u2011JAK inhibitor, Anzupgo (Delgocitinib cream), was written at the Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital. The approval, granted under the Greater Bay Area Access Policy for Drugs and Medical Devices in July\u202f2025, marks the drug\u2019s official entry into mainland Greater Bay Area medical institutions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42383\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42383#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"Denmark-based dermatology specialist LEO Pharma A\/S announced that the Greater Bay Area\u2019s first prescription of its first\u2011in\u2011class topical pan\u2011JAK inhibitor, Anzupgo (Delgocitinib cream), was written at the Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital. The approval, granted under the Greater Bay Area Access Policy for Drugs and Medical Devices in July\u202f2025, marks the drug\u2019s official entry into mainland Greater Bay Area medical institutions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42383","og_locale":"en_US","og_type":"article","og_title":"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor","og_description":"Denmark-based dermatology specialist LEO Pharma A\/S announced that the Greater Bay Area\u2019s first prescription of its first\u2011in\u2011class topical pan\u2011JAK inhibitor, Anzupgo (Delgocitinib cream), was written at the Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital. The approval, granted under the Greater Bay Area Access Policy for Drugs and Medical Devices in July\u202f2025, marks the drug\u2019s official entry into mainland Greater Bay Area medical institutions.","og_url":"https:\/\/flcube.com\/?p=42383","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-28T02:55:00+00:00","article_modified_time":"2025-09-28T02:55:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42383#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42383"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor","datePublished":"2025-09-28T02:55:00+00:00","dateModified":"2025-09-28T02:55:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42383"},"wordCount":282,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42383#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2802.webp","keywords":["Auto-immune","Boao Lecheng pilot zone","LEO Pharma"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42383#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42383","url":"https:\/\/flcube.com\/?p=42383","name":"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42383#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42383#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2802.webp","datePublished":"2025-09-28T02:55:00+00:00","dateModified":"2025-09-28T02:55:01+00:00","description":"Denmark-based dermatology specialist LEO Pharma A\/S announced that the Greater Bay Area\u2019s first prescription of its first\u2011in\u2011class topical pan\u2011JAK inhibitor, Anzupgo (Delgocitinib cream), was written at the Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital. The approval, granted under the Greater Bay Area Access Policy for Drugs and Medical Devices in July\u202f2025, marks the drug\u2019s official entry into mainland Greater Bay Area medical institutions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42383#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42383"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42383#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2802.webp","width":1080,"height":608,"caption":"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42383#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leo\u202fPharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42383"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42383\/revisions"}],"predecessor-version":[{"id":42385,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42383\/revisions\/42385"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42384"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}